With Latest RA Deal, Janssen Seeks To Improve Outcomes With Small Molecules
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen gets option to Modern’s small-molecule candidates for rheumatoid arthritis that could address both the inflammatory and bone-damaging effects of the disease. An R&D exec says the compounds could be complementary to, or used in combination with, Remicade and Simponi, or as standalone RA therapies.